Clinical Trial Update: An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV) [Phase 2]

View source ↗

Summary

An open-label, single-center Phase 2 study is evaluating roflumilast foam 0.3% in pediatric patients with non-segmental vitiligo and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-segmental Vitiligo

Drugs mentioned

• Roflumilast Foam 0.3% (roflumilast)

Snippet

Sponsor: Derm Texas, PLLC | Conditions: Non-segmental Vitiligo | Phase 2 | Status: RECRUITING